Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.

McNeil LK, Zagursky RJ, Lin SL, Murphy E, Zlotnick GW, Hoiseth SK, Jansen KU, Anderson AS.

Microbiol Mol Biol Rev. 2013 Jun;77(2):234-52. doi: 10.1128/MMBR.00056-12. Review.

2.

A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups.

Hoiseth SK, Murphy E, Andrew L, Vogel U, Frosch M, Hellenbrand W, Abad R, Vazquez JA, Borrow R, Findlow J, Taha MK, Deghmane AE, Caugant DA, Kriz P, Musilek M, Mayer LW, Wang X, Macneil JR, York L, Tan CY, Jansen KU, Anderson AS.

Pediatr Infect Dis J. 2013 Oct;32(10):1096-101. doi: 10.1097/INF.0b013e31829aa63b.

PMID:
23694830
3.

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States.

Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, Schmink S, Muzzi A, Bambini S, Rappuoli R, Pizza M, Murphy E, Hoiseth SK, Jansen KU, Anderson AS, Harrison LH, Clark TA, Messonnier NE, Mayer LW.

Vaccine. 2011 Jun 24;29(29-30):4739-44. doi: 10.1016/j.vaccine.2011.04.092. Epub 2011 May 13.

PMID:
21571026
4.

Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity.

Murphy E, Lin SL, Nunez L, Andrew L, Fink PS, Dilts DA, Hoiseth SK, Jansen KU, Anderson AS.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:51-9. Epub 2011 Jan 1.

PMID:
21245656
5.

Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa.

Mothibeli KM, du Plessis M, von Gottberg A, Murphy E, Hoiseth SK, Zlotnick G, Klugman KP.

Vaccine. 2011 Mar 3;29(11):2187-92. doi: 10.1016/j.vaccine.2010.11.072. Epub 2010 Dec 7.

PMID:
21144918
6.

Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage.

Ala'aldeen DA, Flint M, Oldfield NJ, Omer SA, McNeil LK, Jiang Q, Murphy E, Giardina PC, Novikova EG, Dodge-Scully IL, Bayliss CD, Turner DP, Neal KR, Hoiseth SK, Jansen KU, Anderson AS.

Vaccine. 2010 Nov 10;28(48):7667-75. doi: 10.1016/j.vaccine.2010.09.038. Epub 2010 Sep 25.

PMID:
20875489
7.

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.

Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS.

Vaccine. 2010 Aug 23;28(37):6086-93. doi: 10.1016/j.vaccine.2010.06.083. Epub 2010 Jul 7.

PMID:
20619376
8.

NMR dynamics and antibody recognition of the meningococcal lipidated outer membrane protein LP2086 in micellar solution.

Mascioni A, Moy FJ, McNeil LK, Murphy E, Bentley BE, Camarda R, Dilts DA, Fink PS, Gusarova V, Hoiseth SK, Malakian K, Mininni T, Novikova E, Lin S, Sigethy S, Zlotnick GW, Tsao DH.

Biochim Biophys Acta. 2010 Feb;1798(2):87-93. doi: 10.1016/j.bbamem.2009.09.021. Epub 2009 Oct 14.

9.

Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.

Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant DA, Alvestad T, Mayer LW, Sacchi CT, Wang X, Martin D, von Gottberg A, du Plessis M, Klugman KP, Anderson AS, Jansen KU, Zlotnick GW, Hoiseth SK.

J Infect Dis. 2009 Aug 1;200(3):379-89. doi: 10.1086/600141.

PMID:
19534597
10.

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.

McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott AA, Tan C, Mack M, DaSilva I, Alexander K, Mason K, Jiang HQ, Zhu D, Mininni TL, Zlotnick GW, Hoiseth SK, Jones TR, Pride MW, Jansen KU, Anderson AS.

Vaccine. 2009 May 26;27(25-26):3417-21. doi: 10.1016/j.vaccine.2009.01.075. Epub 2009 Feb 5.

PMID:
19200847
11.

Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086.

Mascioni A, Bentley BE, Camarda R, Dilts DA, Fink P, Gusarova V, Hoiseth SK, Jacob J, Lin SL, Malakian K, McNeil LK, Mininni T, Moy F, Murphy E, Novikova E, Sigethy S, Wen Y, Zlotnick GW, Tsao DH.

J Biol Chem. 2009 Mar 27;284(13):8738-46. doi: 10.1074/jbc.M808831200. Epub 2008 Dec 22.

12.

Genes involved in Haemophilus influenzae type b capsule expression are frequently amplified.

Corn PG, Anders J, Takala AK, Käyhty H, Hoiseth SK.

J Infect Dis. 1993 Feb;167(2):356-64.

PMID:
8421169
14.

Amplification status of capsule genes in Haemophilus influenzae type b clinical isolates.

Hoiseth SK, Corn PG, Anders J.

J Infect Dis. 1992 Jun;165 Suppl 1:S114. No abstract available.

PMID:
1588141
15.

Molecular epidemiology of Haemophilus influenzae within families in Santiago, Chile.

Lagos R, Avendano A, Horwitz I, Musser JM, Hoiseth SK, Maneval DR Jr, Jones MJ, Levine MM, Dattas JP, Prenzel I, et al.

J Infect Dis. 1991 Dec;164(6):1149-53.

PMID:
1955714
16.

Potential virulence factors of Haemophilus influenzae biogroup aegyptius in Brazilian purpuric fever. The Brazilian Purpuric Fever Study Group.

Carlone GM, Gorelkin L, Gheesling LL, Hoiseth SK, Mulks MH, O'Connor SP, Weyant RS, Myrick JE, Mayer LW, Arko RJ.

Pediatr Infect Dis J. 1989 Apr;8(4):245-7. No abstract available.

PMID:
2785676
17.

Potential virulence-associated factors in Brazilian purpuric fever. Brazilian Purpuric Fever Study Group.

Carlone GM, Gorelkin L, Gheesling LL, Erwin AL, Hoiseth SK, Mulks MH, O'Connor SP, Weyant RS, Myrick J, Rubin L, et al.

J Clin Microbiol. 1989 Apr;27(4):609-14. Review. No abstract available.

18.

The relationship between type b and nontypable Haemophilus influenzae isolated from the same patient.

Hoiseth SK, Gilsdorf JR.

J Infect Dis. 1988 Sep;158(3):643-5. No abstract available.

PMID:
3261764
19.
20.

Genetics of spontaneous, high-frequency loss of b capsule expression in Haemophilus influenzae.

Hoiseth SK, Connelly CJ, Moxon ER.

Infect Immun. 1985 Aug;49(2):389-95.

21.

Genes aroA and serC of Salmonella typhimurium constitute an operon.

Hoiseth SK, Stocker BA.

J Bacteriol. 1985 Jul;163(1):355-61.

22.

Aromatic-dependent Salmonella dublin as a parenteral modified live vaccine for calves.

Smith BP, Reina-Guerra M, Stocker BA, Hoiseth SK, Johnson E.

Am J Vet Res. 1984 Nov;45(11):2231-5.

PMID:
6395725
23.

Vaccination of calves against Salmonella dublin with aromatic-dependent Salmonella typhimurium.

Smith BP, Reina-Guerra M, Stocker BA, Hoiseth SK, Johnson EH.

Am J Vet Res. 1984 Sep;45(9):1858-61.

PMID:
6388442
24.

Aromatic-dependent Salmonella typhimurium as modified live vaccines for calves.

Smith BP, Reina-Guerra M, Hoiseth SK, Stocker BA, Habasha F, Johnson E, Merritt F.

Am J Vet Res. 1984 Jan;45(1):59-66.

PMID:
6367561
25.

Aromatic-dependent "Salmonella sp." as live vaccine in mice and calves.

Stocker BA, Hoiseth SK, Smith BP.

Dev Biol Stand. 1983;53:47-54.

PMID:
6307785
26.

Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines.

Hoiseth SK, Stocker BA.

Nature. 1981 May 21;291(5812):238-9. No abstract available.

PMID:
7015147

Supplemental Content

Loading ...
Support Center